Skip to main content
. 2022 Feb 24;14(2):e22575. doi: 10.7759/cureus.22575

Table 5. Veliparib as monotherapy.

BRCA: breast cancer-associated

Clinical trial Phase Study objective Germline mutations Somatic mutations Outcomes
Veliparib monotherapy
NCT00892736 [43] I Refractory BRCA1/2-mutated solid cancer; platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer; or basal-like breast cancer Refractory BRCA1/2-mutated solid cancer BRCA-positive patients had about a 58% response rate. Pancreatic data are limited